Abstracts tagged "gout"

Abstract Number: 169 • 2014 ACR/ARHP Annual Meeting
Is Gout a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?
Jasvinder A. Singh¹, Rekha Ramachandaran², Jie Zhang³, Fenglong Xie⁴, Shuo Yang⁵, Huifeng Yun⁶ and Jeffrey R. Curtis², ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL
Background/Purpose: Diabetes is a well-recognized risk factor for heart disease, increasing the risk of heart disease by 2-3 fold in many studies. Recent ACC/AHA lipid…
Abstract Number: 2962 • 2014 ACR/ARHP Annual Meeting
Association of the Toll-like Receptor 4 (TLR4) Gene with Gout
Humaira Rasheed¹, Ruth Topless¹, Richard Day², Diluk Kannangara³, Kenneth Williams³, Linda Bradbury⁴, Matthew Brown⁵, Catherine Hill⁶, Susan Lester⁷, Maureen Rischmueller⁸, Malcolm Smith⁹, Mariano Andrés¹⁰, Thomas Bardin¹¹, Michael Doherty¹², Matthijs Janssen¹³, Tim Jansen¹⁴, Leo Joosten¹⁵, Fernando Perez-Ruiz¹⁶, Timothy Radstake¹⁷, Philip L. Riches¹⁸, Ed Roddy¹⁹, Anne-Kathrin Tausche²⁰, Lisa K. Stamp²¹, Nicola Dalbeth²², Frederic Lioté²³, Alex So²⁴, Cushla McKinney¹ and Tony R. Merriman¹, ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²Dept of Clin Pharmacology, St. Vincent's Hospital, Sydney, Australia, ³University of New South Wales, Sydney, Australia, ⁴The University of Queensland, Brisbane, Australia, ⁵University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Queen Elizabeth Hospital, Adelaide, Australia, ⁷Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia, ⁸Department of Rheumatology, The Queen Elizabeth Hospital, SA, Australia, ⁹Rheumatology Unit Repatriation, Queen Elizabeth Hospital, Adelaide, Australia, ¹⁰Rheumatology Section, Hospital General Universitario de Alicante, Alicante, Spain, ¹¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ¹²Academic Rheumatology, City Hospital, Nottingham, United Kingdom, ¹³Department of Rheumatology, Rijnstate Hospital, Arnhem, Netherlands, ¹⁴Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ¹⁵Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ¹⁶Servicio de Reumatologia, Hospital De Cruces, Baracaldo, Spain, ¹⁷University Medical Center Utrecht, Utrecht, Netherlands, ¹⁸Centre for Rheumatic Diseases, University of Edinburgh, Edinburgh, United Kingdom, ¹⁹Research Institute for Primary Care and Health Sciences, Keele University, Staffordshire, United Kingdom, ²⁰Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ²¹University of Otago, Christchurch, New Zealand, ²²Department of Medicine, University of Auckland, Auckland, New Zealand, ²³UFR médicale, Université Paris Diderot, Paris, France, ²⁴Service De Rhumatologie, CHUV, Lausanne, Switzerland
Background/Purpose: Gout results from innate immune response to monosodium urate (MSU) crystals that form in the context of supersaturation of urate. Identification of genetic risk…
Abstract Number: 167 • 2014 ACR/ARHP Annual Meeting
Target Serum Urate: Do Patients Know Their Goal?
Brian W. Coburn¹, Kayli A. Bendlin², Harlan Sayles¹, Kathryn S. Hentzen³, Michaela M. Hrdy³ and Ted R. Mikuls¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²Pharmacy, Omaha VA Medical Center, Omaha, NE, ³Omaha VA Medical Center, Omaha, NE
Background/Purpose: Treat-to-target approaches are used to achieve therapeutic goals in conditions such as diabetes and rheumatoid arthritis. This strategy has also been widely endorsed in…
Abstract Number: 1984 • 2013 ACR/ARHP Annual Meeting
Impact Of Educational Attainment On Health-Related Quality Of Life and Healthcare Utilization Among Veterans With Gout
Cleopatra Aquino-Beaton¹, Jay E. Persselin², Ari Weinreb¹, Meika A Fang¹, Jasvinder A. Singh^3,4, Erin Duffy⁵, David Elashoff⁶, Puja Khanna^7,8 and Dinesh Khanna⁹, ¹Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ²Medicine W-111J Div of Rheum, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ³Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁴Rheumatology, Birmingham VA, Birmingham, AL, ⁵Medicine, University of California Los Angeles, Los Angeles, CA, ⁶Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁷Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ⁸Rheumatology, Ann Arbor VA, Ann Arbor, MI, ⁹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Gout is a debilitating, chronic disease that requires ongoing treatment and effective self-management. Successful gout treatment depends on multiple factors, including educational attainment. Adequate…
Abstract Number: 1186 • 2013 ACR/ARHP Annual Meeting
Use Of High-Dose Allopurinol To Reach Serum Uric Acid Targets In Patients With Gout Across Multiple Countries
Jasvinder A. Singh¹, Chris Storgard², Scott Baumgartner³ and Robert Morlock⁴, ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²4939 Directors Place, Ardea Bioscience, San Diego, CA, ³Ardea Biosciences, San Diego, CA, ⁴Ardea Bioscience, San Diego, CA
Background/Purpose: Allopurinol is the most commonly used urate-lowering therapy (ULT) in the world. Although allopurinol is FDA approved for up to 800 mg/d and EMEA…
Abstract Number: 1987 • 2013 ACR/ARHP Annual Meeting
LIVER Outcomes In Gout Patients Treated With Febuxostat and Altered LIVER Function TESTS
Fernando Perez-Ruiz^1,2 and Ana M. Herrero-Beites^2,3, ¹Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ²BioCruces Health Research Institute, Baracaldo, Spain, ³Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain
LIVER OUTCOMES IN GOUT PATIENTS TREATED WITH FEBUXOSTAT AND ALTERED LIVER FUNCTION TESTSBackground/Purpose: patients with significantly altered liver function test (LFTs) at screening do not…
Abstract Number: 1187 • 2013 ACR/ARHP Annual Meeting
A Large-Scale, Multicenter, Prospective, Open-Label, 6-Month Study To Evaluate The Safety Of Allopurinol Monotherapy In Patients With Gout
Michael A. Becker¹, David Fitz-Patrick², Chris Storgard³, Matt Cravets⁴ and Scott Baumgartner⁵, ¹Medicine, University of Chicago, Chicago, IL, ²East-West Medical Research Institute, Honolulu, HI, ³4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁴Ardea Biosciences, Inc., San Diego, CA, ⁵Ardea Biosciences, San Diego, CA
Background/Purpose: Documentation of the safety profile of allopurinol at doses ≥300 mg/day is important for its ongoing use as first-line monotherapy or in combination with…
Abstract Number: 1988 • 2013 ACR/ARHP Annual Meeting
Self-Reported Gout, Comorbidities and Healthcare Resource Utilization Data From The 2012 United States National Health and Wellness Survey
Jasvinder A. Singh¹, Kathy Annunziata² and Puja Khanna³, ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²Kantar Health, Princeton, NJ, ³Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Hyperuricemia and gout are associated with major cardiovascular and metabolic comorbidities. Recently published data on comorbidities and gout epidemiology in the US have been…
Abstract Number: 1188 • 2013 ACR/ARHP Annual Meeting
An Assessment Of The Response Of Chronic, Occult, Synovial-Based Inflammation Of Gout To Serum Urate Lowering Therapy
John D. Carter¹, Michelle Patelli², Scott Anderson², Neelish Prakash², Robyn Aydelott², Ernesto Rodriguez², Helen E. Bateman³, Ashley G. Sterrett⁴, Joanne Valeriano-Marcet⁵ and Louis R. Ricca⁶, ¹Internal Medicine; Division of Rheumatology, University of South Florida, Tampa, FL, ²University of South Florida, Tampa, FL, ³Medicine / Rheumatology (111K), James A Haley VA Hospital USF, Tampa, FL, ⁴Internal Medicine/Rheumatology, JAHVA, Tampa, FL, ⁵Internal Medicine, University of South Florida, Tampa, FL, ⁶University of South Florida College of Medicine, St Petersburg, FL
Background/Purpose: We recently demonstrated that synovitis is present in the vast majority of patients with inter-critical gout and that the severity of this synovitis did…
Abstract Number: 1873 • 2013 ACR/ARHP Annual Meeting
Use Of Mendelian Randomization Associates Increased Serum Urate Caused By Genetic Variation In Uric Acid Transporters With Improved Renal Function
Tony R. Merriman¹, Tanya Flynn², Janak de Zoysa³, Nicola Dalbeth⁴ and Kim Hughes², ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Waitemata District Health Board, Auckland, New Zealand, ⁴Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Hyperuricemia is the central risk factor for gout. In observational studies hyperuricemia also predicts the development and progression of chronic kidney disease independent of…
Abstract Number: 1189 • 2013 ACR/ARHP Annual Meeting
Allopurinol Dose Titration and Efficacy: A Large-Scale, 6-Month, Multicenter, Prospective Study
Scott Baumgartner¹, Hyon Choi^2,3, Nicola Dalbeth⁴, David Fitz-Patrick⁵, Matt Cravets⁶ and Chris Storgard⁷, ¹Ardea Biosciences, San Diego, CA, ²Section of Rheumatology and the Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Auckland District Health Board, Auckland, New Zealand, ⁵East-West Medical Research Institute, Honolulu, HI, ⁶Ardea Biosciences, Inc., San Diego, CA, ⁷4939 Directors Place, Ardea Bioscience, San Diego, CA
Background/Purpose: Allopurinol is the first-line urate-lowering therapy (ULT) for most people with gout, but target serum uric acid (sUA) levels of 200-300 >300-400 >400-500 >500-600…
Abstract Number: 160 • 2013 ACR/ARHP Annual Meeting
Association Analysis Of The Organic Anion Transporter 4 and Urate Transporter 1 Locus With Gout In New Zealand Case-Control Sample Sets Reveals Multiple Ancestral-Specific Effects
Tony R. Merriman¹, Amanda Phipps-Green¹, Jade E. Hollis-Moffatt², Marilyn E. Merriman¹, Ruth Topless¹, Grant Montgomery³, Brett Chapman³, Lisa K. Stamp⁴, Nicola Dalbeth⁵ and Tanya Flynn², ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Queensland Institute of Medical Research, Brisbane, Australia, ⁴University of Otago, Christchurch, New Zealand, ⁵Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: There are genetic variants in urate transporters SLC22A11 (OAT4) and SLC22A12 (URAT1) that influence serum urate levels in European Caucasian. However, there is no…
Abstract Number: 1723 • 2013 ACR/ARHP Annual Meeting
Lesinurad, An Inhibitor Of The Uric Acid Transporter URAT1 and a Potential Therapy For Gout, Requires URAT1 Phenylalanine 365 For High Affinity Inhibition
Philip K. Tan, David Hyndman and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout is caused by a lack of efficient excretion of uric acid, resulting in hyperuricemia and the formation of crystal deposits of uric acid. …
Abstract Number: 1190 • 2013 ACR/ARHP Annual Meeting
The Synergistic Effects Of Metabolic Syndrome Indicators and Hyperuricemia In Contributing To Cardiac Event Risk: A Cross-Sectional Examination Of The Nhanes III Data
Daniel A. Albert^1,2 and Sayyad Kyazimzade³, ¹Medicine/Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Rheumatology, The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, ³The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, Lebanon, NH
Background/Purpose: The focus of this project is to assess the contribution of hyperuricemia and gout to the risk for cardiovascular events. In a preliminary analysis…
Abstract Number: 163 • 2013 ACR/ARHP Annual Meeting
The Frequency Of Single Nucleotide Polymorphisms In Urate Transporter Genes and Their Association With Uric Acid Concentration Based On Data From Genome-Wide Association Studies In The Korean Population
Chan-Nam Son¹, So-Young Bang², Sang-Cheol Bae³ and Jae-Bum Jun³, ¹Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea, ²Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ³Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Gouty arthritis is characterized by hyperuricemia, which results from overproduction of, or impaired renal excretion of, uric acid. Recently, interest has increased in renal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].